Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single ascending dose /multiple ascending dose study evaluating NMRA-266 in healthy adult participants. NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. Neumora believes that as a selective M4 receptor-positive allosteric modulator, NMRA-266 has the potential to deliver antipsychotic efficacy, while minimizing the side effects associated with current antipsychotics and other non-selective muscarinic agonists.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.19 USD | -5.94% | -0.65% | -46.10% |
May. 07 | Neumora Therapeutics Shares Fall as Q1 Loss Narrows | MT |
May. 07 | Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.10% | 1.47B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+46.62% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study